{"id":296416,"date":"2025-03-18T00:00:00","date_gmt":"2025-03-18T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0026-2023-biopharma-parkinsons-disease-unmet-need-unmet-need-levodopa-induced-dyskinesia-us\/"},"modified":"2026-04-24T05:12:42","modified_gmt":"2026-04-24T05:12:42","slug":"unnecg0026-2025-biopharma-parkinsons-disease-unmet-need-unmet-need-levodopa-induced-dyskinesia-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecg0026-2025-biopharma-parkinsons-disease-unmet-need-unmet-need-levodopa-induced-dyskinesia-us-eu\/","title":{"rendered":"Parkinson&#8217;s Disease &#8211; Unmet Need &#8211; Unmet Need &#8211; Levodopa-Induced Dyskinesia (US\/EU)"},"content":{"rendered":"<p>Levodopa-induced dyskinesia (<abbr title=\"levodopa-induced dyskinesia\">LID<\/abbr>) is a complication stemming from the long-term use of levodopa to treat Parkinson\u2019s disease (<abbr title=\"Parkinson's disease\">PD<\/abbr>); it causes abnormal involuntary movements. Surveyed neurologists in the United States estimate that more than one in five of their <abbr title=\"Parkinson's disease\">PD<\/abbr> patients currently experiences <abbr title=\"levodopa-induced dyskinesia\">LID<\/abbr>, which can be disabling and painful and greatly affect patients\u2019 quality of life and activities of daily living. Only a few options are available to treat <abbr title=\"Parkinson's disease\">PD<\/abbr>&#8211;<abbr title=\"levodopa-induced dyskinesia\">LID<\/abbr>, including amantadine <abbr title=\"immediate release\">IR<\/abbr>, a long-standing generic drug that is not specifically approved for <abbr title=\"levodopa-induced dyskinesia\">LID<\/abbr> and has an unfavorable side-effect profile. In the United States, Supernus\u2019s Gocovri (amantadine <abbr title=\"extended release\">ER<\/abbr>) is the only <abbr title=\"Food and Drug Administration\">FDA<\/abbr>-approved treatment for <abbr title=\"Parkinson's disease\">PD<\/abbr>&#8211;<abbr title=\"levodopa-induced dyskinesia\">LID<\/abbr>. Research suggests that Supernus\u2019s Xadago has antiglutamatergic properties that may positively impact <abbr title=\"levodopa-induced dyskinesia\">LID<\/abbr>. In addition, newly launched levodopa formulations (e.g., AbbVie\u2019s Vyalev, Amneal\u2019s Crexont) may prove effective in minimizing the emergence of <abbr title=\"levodopa-induced dyskinesia\">LID<\/abbr>. Understanding prescriber perceptions of the available options for <abbr title=\"Parkinson's disease\">PD<\/abbr>&#8211;<abbr title=\"levodopa-induced dyskinesia\">LID<\/abbr> and the drivers behind prescribers\u2019 clinical decision-making for the indication can help drug developers identify levers for new product positioning and differentiation.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What clinical endpoints and drug attributes are most influential in prescribing for <abbr title=\"Parkinson's disease\">PD<\/abbr>&#8211;<abbr title=\"levodopa-induced dyskinesia\">LID<\/abbr>? How do neurologists rate the performance of amantadine, Gocovri, Xadago, and Vyalev on these attributes?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in the treatment of <abbr title=\"Parkinson's disease\">PD<\/abbr>&#8211;<abbr title=\"levodopa-induced dyskinesia\">LID<\/abbr>?<\/li>\n<li>Based on conjoint analysis and <abbr title=\"Target Product Profile\">TPP<\/abbr> simulation, what trade-offs among efficacy, safety, and price are neurologists willing to make for a hypothetical new drug for <abbr title=\"Parkinson's disease\">PD<\/abbr>&#8211;<abbr title=\"levodopa-induced dyskinesia\">LID<\/abbr>?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><a>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/a><\/p>\n<ul class=\"round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<li>Analyze market scenarios for different target product profiles using the <abbr title=\"Target Product Profile\">TPP<\/abbr> Simulator.<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 61 U.S. and 31 European neurologists fielded in January 2025<\/p>\n<p><strong>Key drugs:<\/strong> amantadine <abbr title=\"immediate release\">IR<\/abbr>, Xadago, Gocovri, Crexont, Vyalev<\/p>\n<p><strong>Key feature:<\/strong> Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.<\/p>\n","protected":false},"template":"","class_list":["post-296416","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-neurology","biopharma-therapy-areas-parkinsons-disease","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296416","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296416\/revisions"}],"predecessor-version":[{"id":416578,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296416\/revisions\/416578"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296416"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}